Gaudium IVF and Women Health is set to make a landmark debut on the stock market with its initial public offering (IPO) opening on February 20, 2026. This Rs 165 crore public issue is notable for being the first-ever IPO in India’s fertility care sector, marking an important step forward not only for the company but also for the rapidly growing assisted reproductive technology (ART) industry in the country.

The company has fixed its price band between Rs 75 and Rs 79 per share, aiming to raise Rs 165 crore through this offer. With this move, Gaudium IVF and Women Health is positioning itself as a key player, valued at approximately Rs 575 crore, to fuel its expansion plans and consolidate its position in a niche but fast-developing healthcare segment.

Gaudium IVF operates primarily in the assisted reproductive technology space, offering specialized treatments like In Vitro Fertilisation (IVF), among others. The demand for fertility treatments in India is increasing steadily due to greater awareness, lifestyle changes, and delayed parenthood trends, which makes this IPO not only timely but also potentially lucrative for investors keeping an eye on emerging healthcare markets.

The funds raised from the IPO will be primarily used to expand the company’s network of IVF centers across India and to repay existing debt, which indicates a strategic approach to strengthening operational capabilities and improving the financial health of the company.

Investors have shown growing interest in healthcare and biotech sectors, but fertility care has remained a relatively untapped area in terms of public market participation. Gaudium’s listing thus opens a new avenue for investors to gain exposure to this specialized segment. Given the volatility in broader markets recently, sector-specific plays like this could attract investors looking for growth in emerging niches.

The broader market context is one of mixed performances with oscillating global cues affecting domestic sentiments, but healthcare continues to be an area of focus given its essential nature and growth potential. Gaudium IVF’s move to go public might also inspire other companies in related fields to consider similar fund-raising activities.

To sum up, Gaudium IVF and Women Health’s Rs 165 crore IPO offers a unique opportunity for investors to participate in the growth story of India’s fertility care sector. With the IPO opening on February 20, 2026, market participants keen on diversifying into specialized healthcare sub-sectors will find this offering worth considering. As the first mover in this particular sector IPO, Gaudium IVF sets a precedent and possibly paves the way for more fertility-focused companies to enter the public markets in the future.